SCHEDULE: BVF Funds Exit Repare Therapeutics Post-Acquisition

BVF Partners and affiliated entities report ceasing beneficial ownership of Repare Therapeutics Inc. shares following its acquisition by XenoTherapeutics.

Summary

• The reporting persons, including various BVF entities and Mark N. Lampert, no longer beneficially own any shares of Repare Therapeutics Inc.
• This change in ownership is a direct result of Repare Therapeutics Inc. being acquired by Xeno Acquisition Corp., a wholly-owned subsidiary of XenoTherapeutics, Inc.
• The acquisition became effective on January 28, 2026, pursuant to an Arrangement Agreement dated November 14, 2025.
• As part of the acquisition, Repare Therapeutics Inc. shareholders received $2.20 in cash per share and one contingent value right (CVR) per share for potential future cash payments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for the reporting persons, as they successfully exited their investment through an acquisition, realizing a cash component and retaining potential upside via CVRs. For Repare shareholders, it represents a liquidity event with future potential.

Positives

• The reporting persons successfully exited their investment in Repare Therapeutics Inc. through a corporate acquisition.
• Former shareholders of Repare Therapeutics Inc. received immediate liquidity with a cash payment of $2.20 per share.
• The inclusion of a contingent value right (CVR) provides former shareholders with potential for additional future cash payments, offering upside beyond the initial cash consideration.

Negatives

• The reporting persons no longer hold an equity interest in Repare Therapeutics Inc., thereby losing exposure to any future growth or success of the company.
• The ultimate value of the contingent value right (CVR) is uncertain and dependent on future events or milestones, introducing an element of risk.

Risks

• The value of the contingent value right (CVR) is not guaranteed and depends on the achievement of specific future performance metrics or milestones, which may not materialize.
• The reporting persons have no further exposure to the operational or financial performance of Repare Therapeutics Inc. post-acquisition.

Future Outlook

The filing indicates the completion of an acquisition, meaning Repare Therapeutics Inc. will operate as a subsidiary of XenoTherapeutics, Inc. The future outlook for former Repare shareholders now depends on the performance of the contingent value rights.

Industry Context

StockSavvy.ai notes that this acquisition reflects ongoing consolidation within the biotechnology sector, where smaller, innovative companies like Repare Therapeutics are often targets for larger players seeking to expand their pipelines or technology platforms. The use of contingent value rights (CVRs) is a common mechanism in biotech M&A to bridge valuation gaps and share future risks/rewards, particularly for assets in clinical development.

Comparison to Industry Standards

• The acquisition price of $2.20 cash per share plus a CVR is a common structure in biotech M&A, similar to deals where upfront cash is combined with performance-based payouts.
• For example, in the acquisition of Array BioPharma by Pfizer, shareholders received a fixed cash price, while other deals like the acquisition of Synageva BioPharma by Alexion Pharmaceuticals also included CVRs tied to regulatory milestones.
• The specific terms of the CVR would need to be compared to similar CVRs in the industry to assess its relative attractiveness, but details are not provided in this filing.

Stakeholder Impact

• Shareholders (former Repare Therapeutics Inc.): Received $2.20 cash per share and one contingent value right per share, providing liquidity and potential future payments.
• Reporting Persons (BVF entities): Successfully exited their investment in Repare Therapeutics Inc.
• XenoTherapeutics, Inc.: Acquired Repare Therapeutics Inc., expanding its portfolio.

Next Steps

• Realization of potential cash payments from the contingent value rights for former Repare Therapeutics Inc. shareholders.
• Integration of Repare Therapeutics Inc. into XenoTherapeutics, Inc. operations.

Key Dates

Keywords

Repare Therapeutics, XenoTherapeutics, Acquisition, Schedule 13D/A, BVF Partners, Contingent Value Right, Biotechnology, Merger, Shareholder Exit